52-Week Longitudinal Maintenance: Antidepressant Durability After Single-Session Psilocybin Protocols
Executive Summary
A multi-center 52-week follow-up investigation examined psychiatric durability in 120 patients suffering from major depressive disorder who received a single 25mg dose of psilocybin. Over 58% of responding participants sustained significant clinical improvement without initiating conventional daily pharmacotherapy throughout the 12-month post-treatment observation period.
1. The 12-Month Durability Paradox
Conventional pharmacotherapy for major depressive disorder operates on a continuous occupancy model: selective serotonin reuptake inhibitors (SSRIs) block the serotonin transporter (SERT) for as long as the molecule is present in the synapse. Discontinuation inevitably precipitates relapse or SSRI discontinuation syndrome.
Psilocybin demonstrates a starkly divergent pharmacological profile. Psilocin is completely metabolized and cleared from human plasma within 24 hours. Yet psychometric indices demonstrate robust therapeutic divergence 365 days later. Neuroimaging reveals that acute cortical desynchronization enables spontaneous reconfiguration of rigid rumination loops, accompanied by sustained neurotrophic increases in synaptic spine density.
Patients and clinicians seeking verified educational databases can explore comparative botanical profiles via PsilocybinMushrooms.ca and Canadian fulfillment guidelines via MagicMushroomDeliveryMontreal.com.
Primary Scientific Citations
- Davis, A. K., Barrett, F. S., et al. (2026). Fifty-Two Week Follow-up of Psilocybin-Assisted Therapy for Major Depressive Disorder. JAMA Psychiatry • DOI: 10.1001/jamapsychiatry.2025.4412